Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1979 Feb;65(2):303–309. doi: 10.1111/j.1476-5381.1979.tb07831.x

Reversal of Dopa-induced arousal in reserpine-treated rabbits and mice by histidine

YZ Abou, IB Farjo
PMCID: PMC1668619  PMID: 760904

Abstract

1 The behavioural effects induced by histidine were studied in two species. In rabbits, sedation was assessed by the presence of blepharospasm, loss of righting reflex, and loss of response to painful stimuli. In mice, sedation and arousal were assessed by changes in the locomotor activity, exploratory activity, and minimal electroshock seizure threshold.

2 The administration of histidine to normal rabbits or mice, in doses of 800 mg/kg and 1000 mg/kg respectively, had no apparent effect on behaviour. Moreover, it did not affect the behavioural excitation induced by L-DOPA (100 mg/kg i.v. in rabbits and 750 mg/kg i.p. in mice) in these animals.

3 The administration of histidine with or after L-DOPA in reserpine-treated rabbits (2.5 mg/kg i.v.) or mice (5 mg/kg, i.p.) produced sedation. This sedative effect was dose-dependent.

4 The sedative effects induced by histidine after DOPA-induced arousal in reserpine-treated rabbits and mice were prevented by prior injection of the histamine H1-receptor blockers, chlorpheniramine (2.5 mg/kg) or diphenhydramine (5 mg/kg).

5 Imipramine (7 to 10 mg/kg, i.v.)-induced arousal in reserpine-treated rabbits was also reversed by histidine infusion.

6 The infusion of 5-hydroxytryptophan (100 mg/kg, i.v.) with L-DOPA, or of arginine (450 mg/kg, i.v.) with or after L-DOPA, or of histamine (100 μg/kg), i.v.) after L-DOPA, did not affect the DOPA-induced arousal in reserpine-treated rabbits.

7 These findings indicate that histamine, formed centrally from exogenous histidine, and released in increased amounts at the synapses in reserpine-treated animals, possesses a central sedative effect. This effect may be sufficient to antagonize the behavioural excitation induced by high levels of catecholamines in the brain of these animals when aroused by L-DOPA administration.

8 It is concluded that in addition to the other monoamines, histamine may also be implicated in the regulation of brain excitability.

Full text

PDF
303

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abou Y. Z., Adam H. M., Stephen W. R. Concentration of histamine in different parts of the brain and hypophysis of rabbit: effect of treatment with histidine, certain other amino acids and histamine. Br J Pharmacol. 1973 Aug;48(4):577–589. doi: 10.1111/j.1476-5381.1973.tb08244.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ahtee L., Shillito E. The effect of benzodiazepines and atropine on exploratory behaviour and motor activity of mice. Br J Pharmacol. 1970 Oct;40(2):361–371. doi: 10.1111/j.1476-5381.1970.tb09928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Azzaro A. J., Wenger G. R., Craig C. R., Stitzel R. E. Reserpine-induced alterations in brain amines and their relationship to changes in the incidence of minimal electroshock seizures in mice. J Pharmacol Exp Ther. 1972 Mar;180(3):558–568. [PubMed] [Google Scholar]
  4. Bartholini G., Pletscher A. Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine. J Pharm Pharmacol. 1969 May;21(5):323–324. doi: 10.1111/j.2042-7158.1969.tb08258.x. [DOI] [PubMed] [Google Scholar]
  5. Brodie B. B., Comer M. S., Costa E., Dlabac A. The role of brain serotonin in the mechanism of the central action of reserpine. J Pharmacol Exp Ther. 1966 May;152(2):340–349. [PubMed] [Google Scholar]
  6. CARLSSON A., LINDQVIST M., MAGNUSSON T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 1957 Nov 30;180(4596):1200–1200. doi: 10.1038/1801200a0. [DOI] [PubMed] [Google Scholar]
  7. COSTA E., GARATTINI S., VALZELLI L. Interactions between reserpine, chlorpromazine, and imipramine. Experientia. 1960 Oct 15;16:461–463. doi: 10.1007/BF02171155. [DOI] [PubMed] [Google Scholar]
  8. Dolphin A., Jenner P., Marsden C. D. Proceedings: The mechanism of the effect of dopamine-beta-hydroxylase inhibitor FLA-63 on the L-DOPA reversal of reserpine akinesia. Br J Pharmacol. 1975 Jun;54(2):246P–247P. [PMC free article] [PubMed] [Google Scholar]
  9. File S. E. Effects of chlorpromazine on exploration and habituation in the rat. Br J Pharmacol. 1973 Oct;49(2):303–310. doi: 10.1111/j.1476-5381.1973.tb08376.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. GLOWINSKI J., AXELROD J. EFFECT OF DRUGS ON THE UPTAKE, RELEASE, AND METABOLISM OF H3-NOREPINEPHRINE IN THE RAT BRAIN. J Pharmacol Exp Ther. 1965 Jul;149:43–49. [PubMed] [Google Scholar]
  11. HALPERN B. N., NEVEU T., WILSON C. W. The distribution and fate of radioactive histamine in the rat. J Physiol. 1959 Oct;147:437–449. doi: 10.1113/jphysiol.1959.sp006254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. MAXWELL D. R., PALMER H. T. Demonstration of anti-depressant or stimulant properties of imipramine in experimental animals. Nature. 1961 Jul 1;191:84–85. doi: 10.1038/191084a0. [DOI] [PubMed] [Google Scholar]
  13. McKean C. M., Boggs D. E., Peterson N. A. The influence of high phenylalanine and tyrosine on the concentrations of essential amino acids in brain. J Neurochem. 1968 Mar;15(3):235–241. doi: 10.1111/j.1471-4159.1968.tb06202.x. [DOI] [PubMed] [Google Scholar]
  14. Oldendorf W. H. Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection. Am J Physiol. 1971 Dec;221(6):1629–1639. doi: 10.1152/ajplegacy.1971.221.6.1629. [DOI] [PubMed] [Google Scholar]
  15. RUBIN B., MALONE M. H., WAUGH M. H., BURKE J. C. Bioassay of Rauwolfia roots and alkaloids. J Pharmacol Exp Ther. 1957 Jun;120(2):125–136. [PubMed] [Google Scholar]
  16. Richter J. J., Wainer A. Evidence for separate systems for the transport of neutral and basic amino acids across the blood-brain barrier. J Neurochem. 1971 Apr;18(4):613–620. doi: 10.1111/j.1471-4159.1971.tb11991.x. [DOI] [PubMed] [Google Scholar]
  17. Schildkraut J. J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am J Psychiatry. 1965 Nov;122(5):509–522. doi: 10.1176/ajp.122.5.509. [DOI] [PubMed] [Google Scholar]
  18. Schwartz J. C. Histaminergic mechanisms in brain. Annu Rev Pharmacol Toxicol. 1977;17:325–339. doi: 10.1146/annurev.pa.17.040177.001545. [DOI] [PubMed] [Google Scholar]
  19. Shah N. S., Kamano A., Glisson S., Callison D. Studies on the uptake of radiolabeled DOPA, 5-HTP and tryptophan in rat tissues in vivo: effect of methionine, tryptophan and some keto acids. Int J Neuropharmacol. 1968 Mar;7(2):75–86. doi: 10.1016/0028-3908(68)90001-4. [DOI] [PubMed] [Google Scholar]
  20. TABOR H. Metabolic studies on histidine, histamine, and related imidazoles. Pharmacol Rev. 1954 Sep;6(3):299–343. [PubMed] [Google Scholar]
  21. Tyfield L. A., Holton J. B. The effect of high concentrations of histidine on the level of other amino acids in plasma and brain of the mature rat. J Neurochem. 1976 Jan;26(1):101–105. [PubMed] [Google Scholar]
  22. WEIL-MALHERBE H., AXELROD J., TOMCHICK R. Blood-brain barrier for adrenaline. Science. 1959 May 1;129(3357):1226–1227. doi: 10.1126/science.129.3357.1226. [DOI] [PubMed] [Google Scholar]
  23. Wade L. A., Katzman R. Synthetic amino acids and the nature of L-DOPA transport at the blood-brain barrier. J Neurochem. 1975 Dec;25(6):837–842. doi: 10.1111/j.1471-4159.1975.tb04415.x. [DOI] [PubMed] [Google Scholar]
  24. al-Katib H. A., Baba W. I. The action of certain haloalkylamines on some biological activities of bradykinin. Br J Pharmacol. 1969 Jul;36(3):635–641. doi: 10.1111/j.1476-5381.1969.tb08018.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES